Dr Bang speaks with ecancer at ESMO 2016 to discuss outcomes of the GOLD trial, combining olaparib and paclitaxel to treat advanced gastric cancer.
Compared to paclitaxel alone, olaparib extended overall survival and progression free survival, but did not reach a p value indicating statistical significance.
While the trial is negative, Dr Bang describes the outcomes of indicative of a role for olaparib in future studies.
ecancer's filming at ESMO 2016 has been kindly supported by Amgen through the ECMS Foundation. ecancer is editorially independent and there is no influence over content.